These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30221063)

  • 1. The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival.
    Santegoets SJAM; de Groot AF; Dijkgraaf EM; Simões AMC; van der Noord VE; van Ham JJ; Welters MJP; Kroep JR; van der Burg SH
    Oncoimmunology; 2018; 7(8):e1465166. PubMed ID: 30221063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab.
    Santegoets SJ; Stam AG; Lougheed SM; Gall H; Jooss K; Sacks N; Hege K; Lowy I; Scheper RJ; Gerritsen WR; van den Eertwegh AJ; de Gruijl TD
    J Immunother Cancer; 2014; 2():31. PubMed ID: 26196012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
    Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
    J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer.
    Wouters M; Dijkgraaf EM; Kuijjer ML; Jordanova ES; Hollema H; Welters M; van der Hoeven J; Daemen T; Kroep JR; Nijman HW; van der Burg SH
    Oncoimmunology; 2014 Dec; 3(12):e962397. PubMed ID: 25964862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating CD14
    Stenzel AE; Abrams SI; Joseph JM; Goode EL; Tario JD; Wallace PK; Kaur D; Adamson AK; Buas MF; Lugade AA; Laslavic A; Taylor SE; Orr B; Edwards RP; Elishaev E; Odunsi K; Mongiovi JM; Etter JL; Winham SJ; Kaufmann SH; Modugno F; Moysich KB
    Am J Reprod Immunol; 2021 Mar; 85(3):e13343. PubMed ID: 32905653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Monocytic Myeloid-Derived Suppressor Cells in Whole Blood Predict Poor Prognosis in Patients with Plasma Cell Myeloma.
    Bae MH; Park CJ; Suh C
    J Clin Med; 2021 Oct; 10(20):. PubMed ID: 34682840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.
    Chen HM; Ma G; Gildener-Leapman N; Eisenstein S; Coakley BA; Ozao J; Mandeli J; Divino C; Schwartz M; Sung M; Ferris R; Kao J; Wang LH; Pan PY; Ko EC; Chen SH
    Clin Cancer Res; 2015 Sep; 21(18):4073-4085. PubMed ID: 25922428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.
    Ornstein MC; Diaz-Montero CM; Rayman P; Elson P; Haywood S; Finke JH; Kim JS; Pavicic PG; Lamenza M; Devonshire S; Dann P; Schach K; Stephenson A; Campbell S; Emamekhoo H; Ernstoff MS; Hoimes CJ; Gilligan TD; Rini BI; Garcia JA; Grivas P
    Urol Oncol; 2018 Sep; 36(9):405-412. PubMed ID: 29606341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the
    Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Hennart B; Allorge D; van Geel N; Van Gele M; Brochez L
    Oncoimmunology; 2015 Mar; 4(3):e982382. PubMed ID: 25949897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors Influencing the Differentiation of Human Monocytic Myeloid-Derived Suppressor Cells Into Inflammatory Macrophages.
    Bayik D; Tross D; Klinman DM
    Front Immunol; 2018; 9():608. PubMed ID: 29632539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation and characterization of human peripheral blood dendritic cells.
    Thomas R; Davis LS; Lipsky PE
    J Immunol; 1993 Feb; 150(3):821-34. PubMed ID: 7678623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monocytic myeloid-derived suppressor cells generated from rhesus macaque bone marrow enrich for regulatory T cells.
    Zahorchak AF; Perez-Gutierrez A; Ezzelarab MB; Thomson AW
    Cell Immunol; 2018 Jul; 329():50-55. PubMed ID: 29803290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD14+ HLA-DR-/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation.
    Speigl L; Burow H; Bailur JK; Janssen N; Walter CB; Pawelec G; Shipp C
    Breast Cancer Res Treat; 2018 Apr; 168(2):401-411. PubMed ID: 29230664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics of human myeloid-derived suppressor cells after blood draw.
    Grützner E; Stirner R; Arenz L; Athanasoulia AP; Schrödl K; Berking C; Bogner JR; Draenert R
    J Transl Med; 2016 Jan; 14():2. PubMed ID: 26733325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue.
    Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Petersen-Baltussen HM; ter Laan M; Wesseling P; Adema GJ
    J Neuropathol Exp Neurol; 2015 May; 74(5):390-400. PubMed ID: 25853692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of TLR agonists on the differentiation and function of human monocytic myeloid-derived suppressor cells.
    Wang J; Shirota Y; Bayik D; Shirota H; Tross D; Gulley JL; Wood LV; Berzofsky JA; Klinman DM
    J Immunol; 2015 May; 194(9):4215-21. PubMed ID: 25825448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells.
    Apodaca MC; Wright AE; Riggins AM; Harris WP; Yeung RS; Yu L; Morishima C
    J Immunother Cancer; 2019 Aug; 7(1):230. PubMed ID: 31462270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab.
    Sade-Feldman M; Kanterman J; Klieger Y; Ish-Shalom E; Olga M; Saragovi A; Shtainberg H; Lotem M; Baniyash M
    Clin Cancer Res; 2016 Dec; 22(23):5661-5672. PubMed ID: 27178742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation analysis of the proportion of monocytic myeloid-derived suppressor cells in colorectal cancer patients.
    Shirasuna K; Ito M; Matsuda T; Enomoto T; Ohara Y; Yamamoto M; Nishijima S; Ohkohchi N; Kuromitsu S
    PLoS One; 2020; 15(12):e0243643. PubMed ID: 33370317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autocrine TGFβ Is a Survival Factor for Monocytes and Drives Immunosuppressive Lineage Commitment.
    Gonzalez-Junca A; Driscoll KE; Pellicciotta I; Du S; Lo CH; Roy R; Parry R; Tenvooren I; Marquez DM; Spitzer MH; Barcellos-Hoff MH
    Cancer Immunol Res; 2019 Feb; 7(2):306-320. PubMed ID: 30538091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.